Share Price and Basic Stock Data
Last Updated: November 22, 2025, 8:28 am
| PEG Ratio | -2.15 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Tata Chemicals Ltd operates in the chemicals sector, specifically focusing on inorganic products such as caustic soda and soda ash. As of the latest reports, the company’s share price stood at ₹819, with a market capitalization of ₹20,874 Cr. The company’s revenue trajectory has shown fluctuations, with quarterly sales recorded at ₹3,995 Cr in June 2022, peaking at ₹4,407 Cr in March 2023. However, recent quarters indicate a decline, with sales dropping to ₹3,998 Cr in September 2023 and further to ₹3,730 Cr in December 2023. The trailing twelve months (TTM) sales amounted to ₹14,695 Cr, reflecting a decrease from ₹16,789 Cr reported in March 2023. This decline in revenue trends raises concerns regarding the company’s ability to maintain its competitive edge in a challenging market environment, particularly as it faced increasing operational costs.
Profitability and Efficiency Metrics
The profitability of Tata Chemicals has been under pressure, as evidenced by its reported operating profit margin (OPM) of 17% and a return on equity (ROE) of 1.20%. The OPM has experienced considerable volatility, with a high of 25% in June 2022, but declining to just 9% by March 2025. The net profit for the latest fiscal year was recorded at ₹400 Cr, translating to earnings per share (EPS) of ₹9.23. The interest coverage ratio (ICR) stood at a relatively healthy 3.87x, suggesting that the company can cover its interest obligations comfortably. However, the declining trend in profitability metrics, coupled with a low return on capital employed (ROCE) of 3.96%, raises concerns about operational efficiency and the ability to convert sales into profits effectively. These factors highlight the need for strategic initiatives to enhance profit margins amid rising competition.
Balance Sheet Strength and Financial Ratios
Tata Chemicals reported total borrowings of ₹7,495 Cr against reserves of ₹22,103 Cr, indicating a manageable debt level in relation to its equity base. The company’s debt-to-equity ratio stood at 0.29, reflecting a conservative leverage position. However, the current ratio of 1.09 and quick ratio of 0.67 suggest potential liquidity concerns, particularly in meeting short-term obligations. The book value per share was reported at ₹846.82, with a price-to-book (P/B) ratio of 1.02, indicating the stock is trading at a fair valuation relative to its net assets. The company’s cash conversion cycle (CCC) was reported at 53 days, which is relatively efficient compared to industry standards. Overall, while the balance sheet displays strength in terms of equity and manageable debt, the liquidity ratios warrant attention to ensure the company can navigate any operational disruptions effectively.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Tata Chemicals reveals a diversified ownership structure, with promoters holding 37.98% of the shares. Foreign institutional investors (FIIs) accounted for 13.73%, while domestic institutional investors (DIIs) held 22.17%. Public shareholders constituted 26.07% of the total ownership, with the number of shareholders reported at 6,50,693. The stability in promoter holdings suggests a strong commitment to the company’s long-term vision. However, the slight decline in FII participation from 14.43% in December 2022 to 13.73% in the latest report may indicate cautious sentiment among foreign investors. The consistent DII investments signal confidence in the company’s prospects. This mixed sentiment among various investor classes highlights the need for Tata Chemicals to effectively communicate its strategic initiatives to bolster investor confidence and support.
Outlook, Risks, and Final Insight
Looking ahead, Tata Chemicals faces a complex landscape characterized by both opportunities and risks. The company’s focus on expanding its product portfolio and improving operational efficiency is essential for sustaining growth in a competitive market. However, risks such as fluctuating raw material costs and potential regulatory challenges could impact profitability. Additionally, the declining trend in sales and profitability metrics necessitates a strategic reassessment to enhance market positioning. If Tata Chemicals can effectively address these challenges while leveraging its strong balance sheet and investor support, it may be positioned to capitalize on growth opportunities in the chemicals sector. Conversely, failure to adapt to market dynamics may result in prolonged financial pressures, undermining investor confidence and company performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Tata Chemicals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Caprolactam Chemicals Ltd | 23.3 Cr. | 50.6 | 65.0/37.5 | 2,328 | 11.6 | 0.00 % | 0.48 % | 13.7 % | 10.0 |
| Standard Industries Ltd | 107 Cr. | 16.9 | 31.1/16.0 | 20.4 | 0.00 % | 7.81 % | 10.5 % | 5.00 | |
| Gujarat Alkalies & Chemicals Ltd | 4,009 Cr. | 546 | 823/484 | 26,727 | 759 | 2.90 % | 0.34 % | 1.13 % | 10.0 |
| GHCL Ltd | 5,716 Cr. | 596 | 779/511 | 10.0 | 378 | 2.02 % | 24.2 % | 18.6 % | 10.0 |
| Tata Chemicals Ltd | 20,636 Cr. | 810 | 1,146/756 | 63.3 | 877 | 1.36 % | 3.96 % | 1.20 % | 10.0 |
| Industry Average | 6,239.80 Cr | 421.58 | 5,835.46 | 389.00 | 1.09% | 7.11% | 8.14% | 9.17 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,995 | 4,239 | 4,148 | 4,407 | 4,218 | 3,998 | 3,730 | 3,475 | 3,789 | 3,999 | 3,590 | 3,509 | 3,719 |
| Expenses | 2,980 | 3,319 | 3,317 | 3,442 | 3,175 | 3,191 | 3,188 | 3,032 | 3,215 | 3,381 | 3,156 | 3,182 | 3,070 |
| Operating Profit | 1,015 | 920 | 831 | 965 | 1,043 | 807 | 542 | 443 | 574 | 618 | 434 | 327 | 649 |
| OPM % | 25% | 22% | 20% | 22% | 25% | 20% | 15% | 13% | 15% | 15% | 12% | 9% | 17% |
| Other Income | 71 | 102 | 30 | 86 | 67 | 187 | 98 | -861 | 116 | 152 | -10 | 29 | 138 |
| Interest | 80 | 86 | 107 | 133 | 123 | 145 | 132 | 130 | 133 | 145 | 148 | 137 | 147 |
| Depreciation | 213 | 218 | 227 | 234 | 229 | 234 | 246 | 271 | 273 | 277 | 280 | 293 | 280 |
| Profit before tax | 793 | 718 | 527 | 684 | 758 | 615 | 262 | -819 | 284 | 348 | -4 | -74 | 360 |
| Tax % | 20% | 5% | 19% | -1% | 23% | 20% | 26% | 3% | 33% | 23% | 425% | -34% | 12% |
| Net Profit | 637 | 680 | 425 | 692 | 587 | 495 | 194 | -841 | 190 | 267 | -21 | -49 | 316 |
| EPS in Rs | 23.12 | 24.65 | 15.35 | 27.83 | 20.88 | 16.80 | 6.20 | -33.36 | 5.89 | 7.61 | -2.08 | -2.20 | 9.89 |
Last Updated: August 1, 2025, 9:30 pm
Below is a detailed analysis of the quarterly data for Tata Chemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 3,719.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,509.00 Cr. (Mar 2025) to 3,719.00 Cr., marking an increase of 210.00 Cr..
- For Expenses, as of Jun 2025, the value is 3,070.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 3,182.00 Cr. (Mar 2025) to 3,070.00 Cr., marking a decrease of 112.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 649.00 Cr.. The value appears strong and on an upward trend. It has increased from 327.00 Cr. (Mar 2025) to 649.00 Cr., marking an increase of 322.00 Cr..
- For OPM %, as of Jun 2025, the value is 17.00%. The value appears strong and on an upward trend. It has increased from 9.00% (Mar 2025) to 17.00%, marking an increase of 8.00%.
- For Other Income, as of Jun 2025, the value is 138.00 Cr.. The value appears strong and on an upward trend. It has increased from 29.00 Cr. (Mar 2025) to 138.00 Cr., marking an increase of 109.00 Cr..
- For Interest, as of Jun 2025, the value is 147.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 137.00 Cr. (Mar 2025) to 147.00 Cr., marking an increase of 10.00 Cr..
- For Depreciation, as of Jun 2025, the value is 280.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 293.00 Cr. (Mar 2025) to 280.00 Cr., marking a decrease of 13.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 360.00 Cr.. The value appears strong and on an upward trend. It has increased from -74.00 Cr. (Mar 2025) to 360.00 Cr., marking an increase of 434.00 Cr..
- For Tax %, as of Jun 2025, the value is 12.00%. The value appears to be increasing, which may not be favorable. It has increased from -34.00% (Mar 2025) to 12.00%, marking an increase of 46.00%.
- For Net Profit, as of Jun 2025, the value is 316.00 Cr.. The value appears strong and on an upward trend. It has increased from -49.00 Cr. (Mar 2025) to 316.00 Cr., marking an increase of 365.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 9.89. The value appears strong and on an upward trend. It has increased from -2.20 (Mar 2025) to 9.89, marking an increase of 12.09.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 5:24 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15,885 | 17,204 | 14,873 | 10,346 | 10,270 | 10,337 | 10,357 | 10,200 | 12,622 | 16,789 | 15,421 | 14,887 | 14,695 |
| Expenses | 15,200 | 15,305 | 12,777 | 8,249 | 6,926 | 8,538 | 8,411 | 8,693 | 10,317 | 12,969 | 12,574 | 12,934 | 12,748 |
| Operating Profit | 686 | 1,900 | 2,096 | 2,097 | 3,344 | 1,799 | 1,945 | 1,506 | 2,305 | 3,820 | 2,847 | 1,953 | 1,947 |
| OPM % | 4% | 11% | 14% | 20% | 33% | 17% | 19% | 15% | 18% | 23% | 18% | 13% | 13% |
| Other Income | -154 | 183 | 210 | 293 | 262 | 785 | 6,480 | 254 | 486 | 218 | -521 | 287 | 285 |
| Interest | 579 | 461 | 525 | 297 | 326 | 354 | 342 | 367 | 303 | 406 | 530 | 563 | 576 |
| Depreciation | 471 | 463 | 526 | 512 | 518 | 568 | 666 | 759 | 806 | 892 | 980 | 1,123 | 1,138 |
| Profit before tax | -519 | 1,159 | 1,255 | 1,580 | 2,763 | 1,661 | 7,416 | 634 | 1,682 | 2,740 | 816 | 554 | 518 |
| Tax % | 56% | 30% | 20% | 22% | 2% | 17% | 3% | 31% | 16% | 11% | 47% | 30% | |
| Net Profit | -811 | 802 | 1,006 | 1,234 | 2,702 | 1,387 | 7,228 | 436 | 1,405 | 2,434 | 435 | 387 | 400 |
| EPS in Rs | -40.50 | 23.41 | 30.24 | 38.98 | 95.49 | 45.37 | 274.97 | 10.06 | 49.37 | 90.93 | 10.52 | 9.22 | 8.63 |
| Dividend Payout % | -25% | 53% | 33% | 28% | 23% | 28% | 4% | 99% | 25% | 19% | 143% | 119% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 198.89% | 25.44% | 22.66% | 118.96% | -48.67% | 421.12% | -93.97% | 222.25% | 73.24% | -82.13% | -11.03% |
| Change in YoY Net Profit Growth (%) | 0.00% | -173.45% | -2.77% | 96.30% | -167.63% | 469.79% | -515.09% | 316.22% | -149.01% | -155.37% | 71.09% |
Tata Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | 8% |
| 3 Years: | 6% |
| TTM: | -1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -8% |
| 5 Years: | -48% |
| 3 Years: | -40% |
| TTM: | -45% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 25% |
| 3 Years: | -6% |
| 1 Year: | -13% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 5% |
| 3 Years: | 5% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 4:00 am
Balance Sheet
Last Updated: November 9, 2025, 2:00 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 | 255 |
| Reserves | 5,311 | 5,297 | 6,600 | 7,653 | 10,847 | 12,086 | 12,643 | 14,035 | 17,998 | 19,466 | 21,986 | 21,339 | 22,103 |
| Borrowings | 8,393 | 8,379 | 9,090 | 7,072 | 6,108 | 6,130 | 7,702 | 6,933 | 7,024 | 6,296 | 5,563 | 7,072 | 7,495 |
| Other Liabilities | 6,127 | 6,872 | 8,402 | 8,607 | 8,648 | 8,398 | 7,073 | 7,115 | 8,566 | 8,923 | 8,907 | 9,084 | 9,002 |
| Total Liabilities | 20,086 | 20,802 | 24,346 | 23,587 | 25,858 | 26,869 | 27,673 | 28,337 | 33,843 | 34,940 | 36,711 | 37,750 | 38,855 |
| Fixed Assets | 11,007 | 11,359 | 13,431 | 12,644 | 12,787 | 13,551 | 15,356 | 15,261 | 16,044 | 17,092 | 17,861 | 19,600 | 20,171 |
| CWIP | 468 | 189 | 350 | 333 | 409 | 774 | 835 | 1,094 | 1,668 | 2,410 | 2,217 | 1,913 | 2,099 |
| Investments | 441 | 443 | 2,188 | 2,787 | 2,840 | 5,615 | 4,285 | 5,816 | 7,683 | 7,448 | 9,739 | 9,144 | 9,555 |
| Other Assets | 8,171 | 8,811 | 8,377 | 7,822 | 9,822 | 6,929 | 7,198 | 6,167 | 8,448 | 7,990 | 6,894 | 7,093 | 7,030 |
| Total Assets | 20,086 | 20,802 | 24,346 | 23,587 | 25,858 | 26,869 | 27,673 | 28,337 | 33,843 | 34,940 | 36,711 | 37,750 | 38,855 |
Below is a detailed analysis of the balance sheet data for Tata Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 255.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 255.00 Cr..
- For Reserves, as of Sep 2025, the value is 22,103.00 Cr.. The value appears strong and on an upward trend. It has increased from 21,339.00 Cr. (Mar 2025) to 22,103.00 Cr., marking an increase of 764.00 Cr..
- For Borrowings, as of Sep 2025, the value is 7,495.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 7,072.00 Cr. (Mar 2025) to 7,495.00 Cr., marking an increase of 423.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 9,002.00 Cr.. The value appears to be improving (decreasing). It has decreased from 9,084.00 Cr. (Mar 2025) to 9,002.00 Cr., marking a decrease of 82.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 38,855.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 37,750.00 Cr. (Mar 2025) to 38,855.00 Cr., marking an increase of 1,105.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 20,171.00 Cr.. The value appears strong and on an upward trend. It has increased from 19,600.00 Cr. (Mar 2025) to 20,171.00 Cr., marking an increase of 571.00 Cr..
- For CWIP, as of Sep 2025, the value is 2,099.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,913.00 Cr. (Mar 2025) to 2,099.00 Cr., marking an increase of 186.00 Cr..
- For Investments, as of Sep 2025, the value is 9,555.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,144.00 Cr. (Mar 2025) to 9,555.00 Cr., marking an increase of 411.00 Cr..
- For Other Assets, as of Sep 2025, the value is 7,030.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7,093.00 Cr. (Mar 2025) to 7,030.00 Cr., marking a decrease of 63.00 Cr..
- For Total Assets, as of Sep 2025, the value is 38,855.00 Cr.. The value appears strong and on an upward trend. It has increased from 37,750.00 Cr. (Mar 2025) to 38,855.00 Cr., marking an increase of 1,105.00 Cr..
Notably, the Reserves (22,103.00 Cr.) exceed the Borrowings (7,495.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 678.00 | -7.00 | -7.00 | -5.00 | -3.00 | -5.00 | -6.00 | -5.00 | -5.00 | -3.00 | -3.00 | -6.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 74 | 73 | 88 | 74 | 46 | 51 | 56 | 50 | 56 | 57 | 45 | 47 |
| Inventory Days | 96 | 137 | 119 | 244 | 304 | 315 | 347 | 257 | 318 | 282 | 341 | 324 |
| Days Payable | 119 | 138 | 99 | 232 | 307 | 269 | 302 | 256 | 338 | 289 | 320 | 318 |
| Cash Conversion Cycle | 52 | 72 | 107 | 86 | 43 | 97 | 100 | 51 | 35 | 50 | 66 | 53 |
| Working Capital Days | 11 | -4 | 31 | -4 | 27 | -2 | -102 | 27 | -29 | 29 | -22 | -21 |
| ROCE % | 3% | 11% | 11% | 10% | 16% | 9% | 36% | 4% | 8% | 12% | 8% | 4% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Mid-Cap Opportunities Fund - Regular Plan | 4,260,000 | 0.74 | 437.95 | 4,260,000 | 2025-04-22 13:31:13 | 0% |
| Kotak Flexicap Fund - Regular Plan | 3,750,000 | 0.87 | 385.52 | 3,750,000 | 2025-04-22 03:17:28 | 0% |
| Kotak Equity Opportunities Fund - Regular Plan | 2,064,884 | 1.16 | 212.28 | 2,064,884 | 2025-04-22 17:25:36 | 0% |
| Nippon India Growth Fund | 1,561,427 | 0.66 | 160.52 | 1,561,427 | 2025-04-22 17:25:36 | 0% |
| DSP Mid Cap Fund | 1,382,053 | 0.86 | 142.08 | 1,382,053 | 2025-04-22 03:17:28 | 0% |
| DSP Equity Opportunities Fund | 717,459 | 0.69 | 73.76 | 717,459 | 2025-04-22 17:25:36 | 0% |
| HDFC Large and Mid Cap Fund - Regular Plan | 508,000 | 0.33 | 52.22 | 508,000 | 2025-04-22 03:17:28 | 0% |
| Quant Active Fund | 217,000 | 0.27 | 22.31 | 217,000 | 2025-04-22 03:17:28 | 0% |
| Edelweiss Arbitrage Fund | 149,600 | 0.19 | 15.38 | 149,600 | 2025-04-22 03:17:28 | 0% |
| Kotak Multicap Fund | 143,500 | 0.17 | 14.75 | 143,500 | 2025-04-22 03:17:28 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 9.23 | 10.52 | 90.95 | 49.37 | 10.06 |
| Diluted EPS (Rs.) | 9.23 | 10.52 | 90.95 | 49.37 | 10.06 |
| Cash EPS (Rs.) | 53.18 | 52.82 | 130.43 | 77.91 | 45.91 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 846.82 | 906.43 | 809.49 | 751.80 | 594.25 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 846.82 | 906.43 | 809.49 | 751.80 | 594.25 |
| Revenue From Operations / Share (Rs.) | 583.80 | 604.75 | 658.39 | 495.33 | 400.27 |
| PBDIT / Share (Rs.) | 85.41 | 122.86 | 158.43 | 100.49 | 68.09 |
| PBIT / Share (Rs.) | 41.37 | 84.43 | 123.45 | 68.85 | 38.29 |
| PBT / Share (Rs.) | 14.39 | 29.88 | 107.45 | 56.53 | 23.87 |
| Net Profit / Share (Rs.) | 9.14 | 14.39 | 95.45 | 46.27 | 16.11 |
| NP After MI And SOA / Share (Rs.) | 9.21 | 10.51 | 90.86 | 49.35 | 10.06 |
| PBDIT Margin (%) | 14.63 | 20.31 | 24.06 | 20.28 | 17.01 |
| PBIT Margin (%) | 7.08 | 13.96 | 18.75 | 13.90 | 9.56 |
| PBT Margin (%) | 2.46 | 4.94 | 16.32 | 11.41 | 5.96 |
| Net Profit Margin (%) | 1.56 | 2.37 | 14.49 | 9.34 | 4.02 |
| NP After MI And SOA Margin (%) | 1.57 | 1.73 | 13.80 | 9.96 | 2.51 |
| Return on Networth / Equity (%) | 1.08 | 1.20 | 11.74 | 6.88 | 1.79 |
| Return on Capital Employeed (%) | 3.33 | 7.01 | 10.43 | 6.55 | 4.08 |
| Return On Assets (%) | 0.62 | 0.72 | 6.60 | 3.71 | 0.90 |
| Long Term Debt / Equity (X) | 0.19 | 0.13 | 0.28 | 0.20 | 0.36 |
| Total Debt / Equity (X) | 0.29 | 0.22 | 0.30 | 0.37 | 0.38 |
| Asset Turnover Ratio (%) | 0.39 | 0.42 | 0.48 | 0.40 | 0.14 |
| Current Ratio (X) | 1.09 | 1.05 | 1.66 | 1.23 | 1.49 |
| Quick Ratio (X) | 0.67 | 0.63 | 1.15 | 0.90 | 1.11 |
| Inventory Turnover Ratio (X) | 1.01 | 1.07 | 1.22 | 1.22 | 0.50 |
| Dividend Payout Ratio (NP) (%) | 162.55 | 166.41 | 13.72 | 20.25 | 109.30 |
| Dividend Payout Ratio (CP) (%) | 28.12 | 35.73 | 9.90 | 12.34 | 27.59 |
| Earning Retention Ratio (%) | -62.55 | -66.41 | 86.28 | 79.75 | -9.30 |
| Cash Earning Retention Ratio (%) | 71.88 | 64.27 | 90.10 | 87.66 | 72.41 |
| Interest Coverage Ratio (X) | 3.87 | 5.91 | 9.95 | 8.46 | 4.72 |
| Interest Coverage Ratio (Post Tax) (X) | 1.58 | 3.34 | 7.04 | 4.91 | 2.12 |
| Enterprise Value (Cr.) | 28656.05 | 32847.30 | 31130.10 | 31228.96 | 24062.00 |
| EV / Net Operating Revenue (X) | 1.92 | 2.13 | 1.85 | 2.47 | 2.36 |
| EV / EBITDA (X) | 13.16 | 10.48 | 7.71 | 12.20 | 13.87 |
| MarketCap / Net Operating Revenue (X) | 1.48 | 1.79 | 1.48 | 1.97 | 1.88 |
| Retention Ratios (%) | -62.55 | -66.41 | 86.27 | 79.74 | -9.30 |
| Price / BV (X) | 1.02 | 1.24 | 1.26 | 1.36 | 1.34 |
| Price / Net Operating Revenue (X) | 1.48 | 1.79 | 1.48 | 1.97 | 1.88 |
| EarningsYield | 0.01 | 0.01 | 0.09 | 0.05 | 0.01 |
After reviewing the key financial ratios for Tata Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 9.23. This value is within the healthy range. It has decreased from 10.52 (Mar 24) to 9.23, marking a decrease of 1.29.
- For Diluted EPS (Rs.), as of Mar 25, the value is 9.23. This value is within the healthy range. It has decreased from 10.52 (Mar 24) to 9.23, marking a decrease of 1.29.
- For Cash EPS (Rs.), as of Mar 25, the value is 53.18. This value is within the healthy range. It has increased from 52.82 (Mar 24) to 53.18, marking an increase of 0.36.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 846.82. It has decreased from 906.43 (Mar 24) to 846.82, marking a decrease of 59.61.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 846.82. It has decreased from 906.43 (Mar 24) to 846.82, marking a decrease of 59.61.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 583.80. It has decreased from 604.75 (Mar 24) to 583.80, marking a decrease of 20.95.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 85.41. This value is within the healthy range. It has decreased from 122.86 (Mar 24) to 85.41, marking a decrease of 37.45.
- For PBIT / Share (Rs.), as of Mar 25, the value is 41.37. This value is within the healthy range. It has decreased from 84.43 (Mar 24) to 41.37, marking a decrease of 43.06.
- For PBT / Share (Rs.), as of Mar 25, the value is 14.39. This value is within the healthy range. It has decreased from 29.88 (Mar 24) to 14.39, marking a decrease of 15.49.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 9.14. This value is within the healthy range. It has decreased from 14.39 (Mar 24) to 9.14, marking a decrease of 5.25.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 9.21. This value is within the healthy range. It has decreased from 10.51 (Mar 24) to 9.21, marking a decrease of 1.30.
- For PBDIT Margin (%), as of Mar 25, the value is 14.63. This value is within the healthy range. It has decreased from 20.31 (Mar 24) to 14.63, marking a decrease of 5.68.
- For PBIT Margin (%), as of Mar 25, the value is 7.08. This value is below the healthy minimum of 10. It has decreased from 13.96 (Mar 24) to 7.08, marking a decrease of 6.88.
- For PBT Margin (%), as of Mar 25, the value is 2.46. This value is below the healthy minimum of 10. It has decreased from 4.94 (Mar 24) to 2.46, marking a decrease of 2.48.
- For Net Profit Margin (%), as of Mar 25, the value is 1.56. This value is below the healthy minimum of 5. It has decreased from 2.37 (Mar 24) to 1.56, marking a decrease of 0.81.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.57. This value is below the healthy minimum of 8. It has decreased from 1.73 (Mar 24) to 1.57, marking a decrease of 0.16.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.08. This value is below the healthy minimum of 15. It has decreased from 1.20 (Mar 24) to 1.08, marking a decrease of 0.12.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.33. This value is below the healthy minimum of 10. It has decreased from 7.01 (Mar 24) to 3.33, marking a decrease of 3.68.
- For Return On Assets (%), as of Mar 25, the value is 0.62. This value is below the healthy minimum of 5. It has decreased from 0.72 (Mar 24) to 0.62, marking a decrease of 0.10.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 0.2. It has increased from 0.13 (Mar 24) to 0.19, marking an increase of 0.06.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from 0.22 (Mar 24) to 0.29, marking an increase of 0.07.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.39. It has decreased from 0.42 (Mar 24) to 0.39, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 1.5. It has increased from 1.05 (Mar 24) to 1.09, marking an increase of 0.04.
- For Quick Ratio (X), as of Mar 25, the value is 0.67. This value is below the healthy minimum of 1. It has increased from 0.63 (Mar 24) to 0.67, marking an increase of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.01. This value is below the healthy minimum of 4. It has decreased from 1.07 (Mar 24) to 1.01, marking a decrease of 0.06.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 162.55. This value exceeds the healthy maximum of 50. It has decreased from 166.41 (Mar 24) to 162.55, marking a decrease of 3.86.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 28.12. This value is within the healthy range. It has decreased from 35.73 (Mar 24) to 28.12, marking a decrease of 7.61.
- For Earning Retention Ratio (%), as of Mar 25, the value is -62.55. This value is below the healthy minimum of 40. It has increased from -66.41 (Mar 24) to -62.55, marking an increase of 3.86.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 71.88. This value exceeds the healthy maximum of 70. It has increased from 64.27 (Mar 24) to 71.88, marking an increase of 7.61.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.87. This value is within the healthy range. It has decreased from 5.91 (Mar 24) to 3.87, marking a decrease of 2.04.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.58. This value is below the healthy minimum of 3. It has decreased from 3.34 (Mar 24) to 1.58, marking a decrease of 1.76.
- For Enterprise Value (Cr.), as of Mar 25, the value is 28,656.05. It has decreased from 32,847.30 (Mar 24) to 28,656.05, marking a decrease of 4,191.25.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.92. This value is within the healthy range. It has decreased from 2.13 (Mar 24) to 1.92, marking a decrease of 0.21.
- For EV / EBITDA (X), as of Mar 25, the value is 13.16. This value is within the healthy range. It has increased from 10.48 (Mar 24) to 13.16, marking an increase of 2.68.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.48. This value is within the healthy range. It has decreased from 1.79 (Mar 24) to 1.48, marking a decrease of 0.31.
- For Retention Ratios (%), as of Mar 25, the value is -62.55. This value is below the healthy minimum of 30. It has increased from -66.41 (Mar 24) to -62.55, marking an increase of 3.86.
- For Price / BV (X), as of Mar 25, the value is 1.02. This value is within the healthy range. It has decreased from 1.24 (Mar 24) to 1.02, marking a decrease of 0.22.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.48. This value is within the healthy range. It has decreased from 1.79 (Mar 24) to 1.48, marking a decrease of 0.31.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Tata Chemicals Ltd:
- Net Profit Margin: 1.56%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.33% (Industry Average ROCE: 7.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.08% (Industry Average ROE: 8.14%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.58
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.67
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 63.3 (Industry average Stock P/E: 5)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.29
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.56%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Inorganic - Caustic Soda/Soda Ash | Bombay House, 24, Homi Mody Street, Mumbai Maharashtra 400001 | investors@tatachemicals.com http://www.tatachemicals.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. S Padmanabhan | Chairman |
| Mr. R Mukundan | Managing Director & CEO |
| Mr. Modan Saha | Director |
| Mrs. Padmini Khare Kaicker | Independent Director |
| Mr. Rajiv Dube | Independent Director |
| Dr. C V Natraj | Independent Director |
| Mr. K B S Anand | Independent Director |
FAQ
What is the intrinsic value of Tata Chemicals Ltd?
Tata Chemicals Ltd's intrinsic value (as of 26 November 2025) is 540.18 which is 33.31% lower the current market price of 810.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 20,636 Cr. market cap, FY2025-2026 high/low of 1,146/756, reserves of ₹22,103 Cr, and liabilities of 38,855 Cr.
What is the Market Cap of Tata Chemicals Ltd?
The Market Cap of Tata Chemicals Ltd is 20,636 Cr..
What is the current Stock Price of Tata Chemicals Ltd as on 26 November 2025?
The current stock price of Tata Chemicals Ltd as on 26 November 2025 is 810.
What is the High / Low of Tata Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Tata Chemicals Ltd stocks is 1,146/756.
What is the Stock P/E of Tata Chemicals Ltd?
The Stock P/E of Tata Chemicals Ltd is 63.3.
What is the Book Value of Tata Chemicals Ltd?
The Book Value of Tata Chemicals Ltd is 877.
What is the Dividend Yield of Tata Chemicals Ltd?
The Dividend Yield of Tata Chemicals Ltd is 1.36 %.
What is the ROCE of Tata Chemicals Ltd?
The ROCE of Tata Chemicals Ltd is 3.96 %.
What is the ROE of Tata Chemicals Ltd?
The ROE of Tata Chemicals Ltd is 1.20 %.
What is the Face Value of Tata Chemicals Ltd?
The Face Value of Tata Chemicals Ltd is 10.0.